Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Student receives international award in microbiology
2008-01-24

A postgraduate student at the University of the Free State (UFS) received an exceptional honour last month when he received the first prize for his presentation in the Biochemistry and Industrial Mycology session of the Asian Mycology Congress (AMC) held in Malaysia.

Desmond Ncango (24), a Ph.D. student from the Department of Microbial, Biochemical and Food Biotechnology received the first prize for his presentation on the inhibitory effects of non-steroidal anti inflammatory drugs (NSAIDs) such as aspirin on fungi.

This suggests that commonly used aspirin may be used as a cheap antifungal to combat yeast infections. Desmond also exposed novel lubricants that are used by yeasts for water-propelled movement. This may find application in nanotechnology in the lubrication of nanorobots, which are manmade miniature machines, invisible to the naked eye, which may in future be used to combat diseases such as cancer.

The conference, which was attended by more than 300 representatives from 27 countries, is a platform for mycologists (who are experts in fungi) around the world to come together and share their knowledge and research. “Many interested researchers listened to my presentation and were impressed by the novelty and scientific depth of my work,” said Desmond.

“The presentation was selected as the best because of its novelty, academic depth as well as applicability. The meticulous preparation and presentation style also contributed to the success,” said Prof. Lodewyk Kock, head of the Lipid Biotechnology Group at the department and main promoter of Desmond’s Ph.D. studies.

“I cannot really explain the feeling when my presentation was selected as the best as it was presented in a very difficult category and many senior researchers and professors also participated. I plan to use all the knowledge and skills I have learnt from Prof. Kock, who is my role model, especially to the benefit of disadvantage communities in South Africa. I want to follow an academic career at a tertiary institution when I have completed my Ph.D. studies,” said Desmond.

Desmond went to school in Botshabelo, Bloemfontein and completed his Grade 12 in 2000 with a distinction in Mathematics. He enrolled for a B.Sc. degree at the UFS, majoring in Microbiology and Physiology. After obtaining this qualification, he joined the postgraduate research group of Prof. Kock. He completed his M.Sc. degree with distinction last year and was privileged to have this research published in and on the cover of the Canadian Journal of Microbiology, a journal accredited by the Institute for Scientific Information (ISI).

He was one of six postgraduate students from the Lipid Biotechnology Group who attended the AMC conference in Malaysia. The students’ attendance was funded by the South African Fryer Oil Initiative (SAFOI), which is housed in the UFS Department of Microbial, Biochemical and Food Biotechnology. This initiative, steered by Prof. Kock, currently monitors edible oils in the food industry in South Africa and makes a quality seal available to the manufacturers and distributors of these edible oils.

“SAFOI’s income is used to fund my own research on various kinds of oils (including yeast oils) to enable postgraduate students to attend international congresses and to partially fund international scientific symposia and congresses,” said Prof. Kock.

 

Media Release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za 
24 January 2008

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept